Monday, 25 April 2016

Alcove-project

  • Home
  • Aims
    • Context
    • Means
    • Objectives
  • Partners
    • Member States
    • Workpackage Leaders
    • All Partners
  • 4 Core questions
    • Epidemiological dataon dementia
      • Executive Summary
      • Recommendations
    • Timely diagnosisof Dementia
      • Executive Summary
      • Full Final Report
      • References
    • Rights, Autonomy & Dignityof people living with Dementia
      • Executive Summary
      • Recommendations
    • Support Systemsfor BPSD
      • Executive Summary
      • Recommendations
  • ALCOVE in progress
    • Alcove methods
      • Alcove procedures
  • Communication
    • Flyers and Posters
    • Slides
    • Pictures
    • Reports
    • Newsletters
    • Press Releases
    • ALCOVE IN VARIOUS LANGUAGES
  • Glossary
  • TOOLBOX
  • News and Events
    • Alcove News

ANTIPSYCHOTICS’ RISK MEASUREMENT IN EUROPE

risk-measurementThe chronic exposure of people living with Alzheimer's disease to antipsychotics leads to increased severe side effects (falls, excessive sedation, stroke, increase risk of moratlity).  It is crucial to measure and monitor this iatrogenic risk.

Risk exposure in Europe

European projects

Recommendations and Tools

TOOLBOX

  • Home
  • Rationale
  • Antipsychotics Risk Measurement in Europe
    • Risk Exposure in Europe
    • European projects
    • Recommendations and Tools
  • Antipsychotics Risk Reduction
  • Timely Diagnosis & Antipsychotics
  • Ethics in practice & Antipsychotics
  • Behavioural & Psychological Symtoms of Dementia
  • All the Tools
  • ALCOVE Glossary

ALCOVE has received funding from the European Commission in the framework of the Public Health Programme.
Grant Agreement N°2010 22 01

logo EU